Abstract
Background: The number of medical marijuana patients is increasing. This increase raises important concerns about how medical marijuana use may affect parenting.
Methods: Thirty-two adult medical marijuana patients participated in focus groups. The focus groups were audio-recorded and transcribed. The transcriptions were coded by a team that met regularly to resolve coding differences. Codes related to parenting were used to develop a conceptual model for this manuscript.
Results: Six of 11 participants who identified being parents reported that using marijuana helped them to be calmer with their children and to manage difficult emotions related to parenting. At the same time, most medical marijuana patients did not want their children to use marijuana. Their concerns about their children led to different strategies related to storing medical marijuana securely and how to communicate with children about medical marijuana use.
Conclusions: These findings show that many medical marijuana patients are concerned about their children using marijuana and may be open to strategies to addressing this issue with their children. These findings also show that some medical marijuana patients may benefit from alternative strategies for managing difficult emotions related to parenting.
Keywords: Adolescents, marijuana, medical, parenting.
Adolescent Psychiatry
Title:Medical Marijuana Use and Parenting: A Qualitative Study
Volume: 3 Issue: 2
Author(s): Christian Thurstone, Ingrid A. Binswanger, Karen F. Corsi, Deborah J. Rinehart and Robert E. Booth
Affiliation:
Keywords: Adolescents, marijuana, medical, parenting.
Abstract: Background: The number of medical marijuana patients is increasing. This increase raises important concerns about how medical marijuana use may affect parenting.
Methods: Thirty-two adult medical marijuana patients participated in focus groups. The focus groups were audio-recorded and transcribed. The transcriptions were coded by a team that met regularly to resolve coding differences. Codes related to parenting were used to develop a conceptual model for this manuscript.
Results: Six of 11 participants who identified being parents reported that using marijuana helped them to be calmer with their children and to manage difficult emotions related to parenting. At the same time, most medical marijuana patients did not want their children to use marijuana. Their concerns about their children led to different strategies related to storing medical marijuana securely and how to communicate with children about medical marijuana use.
Conclusions: These findings show that many medical marijuana patients are concerned about their children using marijuana and may be open to strategies to addressing this issue with their children. These findings also show that some medical marijuana patients may benefit from alternative strategies for managing difficult emotions related to parenting.
Export Options
About this article
Cite this article as:
Thurstone Christian, A. Binswanger Ingrid, F. Corsi Karen, J. Rinehart Deborah and E. Booth Robert, Medical Marijuana Use and Parenting: A Qualitative Study, Adolescent Psychiatry 2013; 3 (2) . https://dx.doi.org/10.2174/2210676611303020010
DOI https://dx.doi.org/10.2174/2210676611303020010 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design Early β-Amyloid-induced Synaptic Dysfunction Is Counteracted by Estrogen in Organotypic Hippocampal Cultures
Current Alzheimer Research Recent Advances in the Rational Drug Design Based on Multi-target Ligands
Current Medicinal Chemistry Surface Modified Self-Nanoemulsifying Formulations (SNEFs) For Oral Delivery of Gentamicin: In Vivo Toxicological and Pre- Clinical Chemistry Evaluations
Current Nanomedicine Effect of Antioxidant Extract from Cherries on Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Structure- and Ligand-Based Approaches to Evaluate Aporphynic Alkaloids from Annonaceae as Multi-Target Agent Against Leishmania donovani
Current Pharmaceutical Design Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Synthesis, Biological Evaluation and In Silico Study of β-Chloro Vinyl Chalcones as Inhibitors of the TNF-α, IL-6 With Anticancer and Antioxidant Activity
Letters in Drug Design & Discovery Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson`s Disease and Schizophrenia
Current Protein & Peptide Science Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects
Current Cancer Drug Targets Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies Acknowledgements to Reviewers
Current Neuropharmacology Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets